Kyverna Therapeutics, Inc. (KYTX) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Kyverna Therapeutics, Inc. (KYTX).

Download PennyGems on Google Play Download PennyGems on the App Store

Equity Overview

Price & Market Data

Price: $3.31

Daily Change: -$0.02 / 0.60%

Daily Range: $3.27 - $3.44

Market Cap: $143,054,560

Daily Volume: 346,608

Performance Metrics

1 Week: -7.28%

1 Month: 6.43%

3 Months: 63.86%

6 Months: 1.22%

1 Year: -52.98%

YTD: -11.50%

Company Details

Employees: 112

Sector: Health technology

Industry: Biotechnology

Country:

Details

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Selected stocks

Banco Bradesco Sa (BBD)

SunCar Technology Group Inc. (SDA)

Binah Capital Group, Inc. (BCG)